<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Strict//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-strict.dtd"><html xml:lang="en" lang="en" xmlns="http://www.w3.org/1999/xhtml"><head><meta http-equiv="Content-Type" content="text/html; charset=utf-8" /><meta name="ROBOTS" content="NOARCHIVE" /><meta name="googlebot" content="nosnippet" /><meta name="Document-Type" content="" /><meta name="keywords" content="Zoster see Herpes infections; Herpes infections; Dental prescribing: herpes labialis; Dental prescribing: infections: viral; Dental prescribing: herpetic gingivostomatitis; Varicella-zoster; Chickenpox; Aciclovir: herpes zoster; Shingles; Postherpetic neuralgia; Aciclovir: varicella-zoster; Varicella-zoster; Aciclovir: herpes simplex; Aciclovir: herpes simplex: genital; Aciclovir: herpes simplex: eye; Famciclovir; Penciclovir; Valaciclovir; Herpes infections: genital; Idoxuridine; Foscarnet; Inosine pranobex" /><meta name="IX" content="Herpes infections; Dental prescribing: herpes labialis; Dental prescribing: infections: viral; Dental prescribing: herpetic gingivostomatitis; Varicella-zoster; Chickenpox; Aciclovir: herpes zoster; Shingles; Postherpetic neuralgia; Aciclovir: varicella-zoster; Varicella-zoster; Aciclovir: herpes simplex; Aciclovir: herpes simplex: genital; Aciclovir: herpes simplex: eye; Famciclovir; Penciclovir; Valaciclovir; Herpes infections: genital; Idoxuridine; Foscarnet; Inosine pranobex" /><meta name="IXN" content="Zoster see Herpes infections" /><title>5.3.2.1 Herpes simplex and varicella–zoster infection: British National Formulary</title><link type="text/css" rel="stylesheet" href="../../theme/theme.css" /><link type="text/css" rel="stylesheet" href="../../theme/print.css" media="print" /><link type="text/css" rel="stylesheet" href="59/style.css" /><link type="image/x-icon" rel="shortcut icon" href="favicon.ico" /><link rel="stylesheet" type="text/css" href="style/screen.css" media="screen" /><link rel="stylesheet" type="text/css" href="style/print.css" media="print" /><link rel="contents" type="text/html" href="index.htm" /><link rel="help" type="text/html" href="http://www.medicinescomplete.com/mc/help_page.htm" /><link rel="start" type="text/html" href="index.htm" title="British National Formulary" /><link rel="copyright" type="text/html" href="PHP0-publication-information.htm" title="Copyright information" /><link rel="bookmark" title="Skip Navigation" href="PHP3839-herpes-simplex-and-varicellazoster-infection.htm#pB" /><script type="text/javascript" src="https://ajax.googleapis.com/ajax/libs/jquery/1.7.0/jquery.min.js"></script><script type="text/javascript" src="../../scripts/jquery/jquery.tooltip.min.js"></script><script type="text/javascript" src="../../scripts/jquery/jquery.cookie.js"></script><script type="text/javascript" src="../../scripts/jquery/jquery.autosuggest.js"></script><script type="text/javascript" src="../../scripts/scripts.js"></script><style type="text/css">
  .contentsbox { position: fixed; z-index:1001;}
  .contentsbox_wrap {overflow:hidden;width:20px;height:130px; position:absolute;left:0;top:0;}
</style><!--[if lte IE 7]>
          <style type="text/css">
          .contentsbox {
          position: absolute;
          left: expression( ( 15 + ( ignoreMe2 = document.documentElement.scrollLeft ? document.documentElement.scrollLeft : document.body.scrollLeft ) ) + 'px' );
          top: expression( ( 250 + ( ignoreMe = document.documentElement.scrollTop ? document.documentElement.scrollTop : document.body.scrollTop) ) + 'px' );
          }
          .threecol_col3 {
          font-family: arial
          }
          .threecol_col3 a {
          font-family: verdana,helvetica,sans-serif
          }
          .threecol_col1 {
          font-family: arial
          }
          .threecol_col1 a {
          font-family: verdana,helvetica,sans-serif
          }
          div#pE {
          font-family: arial
          }
          div#pE a {
          font-family: verdana,helvetica,sans-serif
          }
          div#pK {
          font-family: arial
          }
          div#pK a {
          font-family: verdana,helvetica,sans-serif
          }
          </style>
          <![endif]--></head><body><?highlighter off?><div id="pU"><a id="pD" accesskey="s" rel="bookmark" href="PHP3839-herpes-simplex-and-varicellazoster-infection.htm#pB" title="Skip Navigation">Skip Navigation</a><img src="../../images/mylogo.png" alt="BNF.org Free Access" id="pI" /><ul id="pZ"><li><a href="http://www.medicinescomplete.com/mc/account.htm">You are signed in as a member of <b>BNF.org Free Access</b></a></li><li> | <a href="http://www.medicinescomplete.com/mc/login.htm">Sign in different user</a></li><li> | <a href="http://www.medicinescomplete.com/mc/logout.htm">Sign out</a></li></ul><a href="http://www.medicinescomplete.com/mc/" title="Go to the MedicinesComplete home page"><img src="../../images/mc.png" alt="MedicinesComplete" /></a><ul id="pM"><li><a href="http://www.medicinescomplete.com/mc/" class="selected" accesskey="1" title="Home: access key 1"><strong><span>Home</span></strong></a></li><li><a href="http://www.medicinescomplete.com/mc/marketing/current/"><strong><span>Welcome</span></strong></a></li><li><a href="http://www.medicinescomplete.com/mc/feedback.htm?pub=bnf&amp;uri=PHP3839-herpes-simplex-and-varicellazoster-infection.htm" accesskey="9" title="Feedback: access key 9"><strong><span>Feedback</span></strong></a></li><li><a href="http://www.medicinescomplete.com/mc/help.htm" accesskey="6" title="Help button: access key 6"><strong><span>Help</span></strong></a></li></ul></div><div id="pA"><div id="pY">British National Formulary</div><div id="pG">Printed from: Joint Formulary Committee.  <i>British National Formulary</i>. [online] London: BMJ Group and Pharmaceutical Press.. &lt; http://www.medicinescomplete.com/ &gt; [Accessed on 06 Oct 2012 (GMT)].</div><div id="pQ"><form id="searchForm" method="get" action="http://www.medicinescomplete.com/mc/bnf/current/search.htm"><fieldset><legend>Details</legend><label for="q">Search for</label><div id="qd"><div><input accesskey="4" type="text" id="q" name="q" /><input class="button" id="searchButton" type="submit" value="Search" name="searchButton" title="Search full text" /></div></div></fieldset></form><script type="text/javascript">$(document).ready(function(){$("#q").autoSuggest('http://www.medicinescomplete.com/mc/bnf/current/search/suggest.xml', {control: "#searchButton"});});</script></div></div><div id="pH"><div id="pN"><div id="pT"><span class="cA"><a href="http://www.medicinescomplete.com/mc/">Home</a></span> &gt; <a href="index.htm">BNF September 2012</a> &gt; <a href="PHP3253-infections.htm">5 Infections</a> &gt; <a href="PHP3742-antiviral-drugs.htm">5.3 Antiviral drugs</a> &gt; <a href="PHP3838-herpesvirus-infections.htm">5.3.2 Herpesvirus infections</a></div><div id="pP"><div class="threecol_col1">◄ <a accesskey="[" href="PHP3838-herpesvirus-infections.htm" title="Previous: 5.3.2 Herpesvirus infections">Previous page</a></div><div class="threecol_col2"> </div><div class="threecol_col3"><a accesskey="]" href="PHP3843-aciclovir.htm" title="Next: ACICLOVIR">Next page</a> ►</div></div></div></div><div id="p1"><div id="pB"><h1><span>5.3.2.1 </span>Herpes simplex and varicella–zoster infection</h1><?highlighter on?><div id="pC" class="jN"><p>The two most important herpesvirus pathogens are herpes simplex virus (herpesvirus hominis) and varicella–zoster virus.</p> <div id="PHP3840"><h2>Herpes simplex infections</h2><p>Herpes infection of the mouth and lips and in the eye is generally associated with herpes simplex virus serotype 1 (HSV-1); other areas of the skin may also be infected, especially in immunodeficiency. Genital infection is most often associated with HSV-2 and also HSV-1. Treatment of herpes simplex infection should start as early as possible and usually within 5 days of the appearance of the infection.</p><p>In individuals with good immune function, mild infection of the eye (ocular herpes, <a title="sub-section: Antivirals" href="PHP6853-antivirals.htm">section 11.3.3</a>) and of the lips (herpes labialis or cold sores, <a title="target-block: herpes labialis" href="PHP8053-antiviral-preparations.htm#PHP8054">section 13.10.3</a>) is treated with a topical antiviral drug. Primary herpetic gingivostomatitis is managed by changes to diet and with analgesics (<a title="monograph-family: Viral infections" href="PHP7393-oropharyngeal-viral-infections.htm">section 12.3.2</a>). Severe infection, neonatal herpes infection or infection in immunocompromised individuals requires treatment with a systemic antiviral drug. Primary or recurrent genital herpes simplex infection is treated with an antiviral drug given by mouth. Persistence of a lesion or recurrence in an immunocompromised patient may signal the development of resistance.</p><p>Specialist advice should be sought for systemic treatment of herpes simplex infection in pregnancy.</p></div> <div id="PHP3841"><h2>Varicella-zoster infections</h2><p>Regardless of immune function and the use of any immunoglobulins, neonates with <em>chickenpox</em> should be treated with a parenteral antiviral to reduce the risk of severe disease. Chickenpox in otherwise healthy children between 1 month and 12 years is usually mild and antiviral treatment is not usually required.</p><p>Chickenpox is more severe in adolescents and adults than in children; antiviral treatment started within 24 hours of the onset of rash may reduce the duration and severity of symptoms in otherwise healthy adults and adolescents. Antiviral treatment is generally recommended in immunocompromised patients and those at special risk (e.g. because of severe cardiovascular or respiratory disease or chronic skin disorder); in such cases, an antiviral is given for 10 days with at least 7 days of parenteral treatment.</p><p>Pregnant women who develop severe chickenpox may be at risk of complications, especially varicella pneumonia. Specialist advice should be sought for the treatment of chickenpox during pregnancy.</p><p>Those who have been exposed to chickenpox and are at special risk of complications may require prophylaxis with varicella-zoster immunoglobulin (see under Disease Specific Immunoglobulins, <a title="BNF:monograph-family: Varicella–zoster" href="PHP8475-varicellazoster.htm">section 14.5.2</a>).</p><p>In <em>herpes zoster</em> (shingles) systemic antiviral treatment can reduce the severity and duration of pain, reduce complications, and reduce viral shedding. Treatment with the antiviral should be started within 72 hours of the onset of rash and is usually continued for 7–10 days. Immunocompromised patients at high risk of disseminated or severe infection should be treated with a parenteral antiviral drug. </p><p>Chronic pain which persists after the rash has healed (postherpetic neuralgia) requires specific management (<a title="BNF:sub-section: Neuropathic pain" href="PHP2814-neuropathic-pain.htm">section 4.7.3</a>).</p></div> <div id="PHP3842"><h2>Choice</h2><p><strong>Aciclovir</strong> is active against herpesviruses but does not eradicate them. Uses of aciclovir include systemic treatment of varicella–zoster and the systemic and topical treatment of herpes simplex infections of the skin (<a title="sub-section: Antiviral preparations" href="PHP8053-antiviral-preparations.htm">section 13.10.3</a>) and mucous membranes (<a title="target-block: herpes genital infections" href="PHP4840-other-infections.htm#PHP4841">section 7.2.2</a>). It is used by mouth for severe herpetic stomatitis (see also <a title="monograph-family: Viral infections" href="PHP7393-oropharyngeal-viral-infections.htm">section 12.3.2</a>). Aciclovir eye ointment (<a title=" Antivirals" href="PHP6853-antivirals.htm">section 11.3.3</a>) is used for herpes simplex infections of the eye; it is combined with systemic treatment for ophthalmic zoster.</p><p><strong>Famciclovir</strong>, a prodrug of penciclovir, is similar to aciclovir and is licensed for use in herpes zoster and genital herpes. Penciclovir itself is used as a cream for herpes simplex labialis (<a title=" Antiviral preparations" href="PHP8053-antiviral-preparations.htm">section 13.10.3</a>).</p><p><strong>Valaciclovir</strong> is an ester of aciclovir, licensed for herpes zoster and herpes simplex infections of the skin and mucous membranes (including genital herpes); it is also licensed for preventing cytomegalovirus disease following solid organ transplantation. Famciclovir or valaciclovir are suitable alternatives to aciclovir for oral lesions associated with herpes zoster. Valaciclovir once daily may reduce the risk of transmitting genital herpes to heterosexual partners—specialist advice should be sought.</p><p><strong>Idoxuridine</strong> (<a title=" Antiviral preparations" href="PHP8053-antiviral-preparations.htm">section 13.10.3</a>) has been used topically for treating herpes simplex infections of the skin and external genitalia with variable results. Its value in the treatment of shingles is unclear.</p><p><strong>Foscarnet</strong> (<a title="BNF:monograph: FOSCARNET SODIUM" href="PHP3864-foscarnet-sodium.htm">section 5.3.2.2</a>) is used for mucocutaneous herpes simplex virus infection unresponsive to aciclovir in immunocompromised patients; it is toxic and can cause renal impairment.</p><p><strong>Inosine pranobex</strong> has been used by mouth for herpes simplex infections; its effectiveness remains unproven.</p></div> </div><div id="pS"><p>Sub-sections</p><ul class="jT"><li id="_PHP3843-aciclovir"><a href="PHP3843-aciclovir.htm" title="ACICLOVIR">ACICLOVIR</a></li><li id="_PHP3848-famciclovir"><a href="PHP3848-famciclovir.htm" title="FAMCICLOVIR">FAMCICLOVIR</a></li><li id="_PHP3851-inosine-pranobex"><a href="PHP3851-inosine-pranobex.htm" title="INOSINE PRANOBEX">INOSINE PRANOBEX</a></li><li id="_PHP3853-valaciclovir"><a href="PHP3853-valaciclovir.htm" title="VALACICLOVIR">VALACICLOVIR</a></li></ul></div><?highlighter off?><div id="pE">◄ <a accesskey="[" href="PHP3838-herpesvirus-infections.htm">Previous: 5.3.2 Herpesvirus infections</a> | <a class="top" href="PHP3839-herpes-simplex-and-varicellazoster-infection.htm#">Top</a> | <a accesskey="]" href="PHP3843-aciclovir.htm">Next: ACICLOVIR</a> ►</div></div></div><div id="pF"><div id="pL"><div id="footer"><div id="footerinner"><ul><li><a accesskey="0" href="accessibility.htm" title="Accessibility information: access key 0">Accessibility</a> | </li><li><a href="http://www.medicinescomplete.com/mc/marketing/current/contact.htm">Contact Us</a> | </li><li><a href="privacy.htm" title="Cookie and Privacy Policy">Cookie and Privacy Policy</a> | </li><li><a accesskey="3" href="http://www.medicinescomplete.com/mc/sitemap.htm" title="Site Map: access key 3">Site Map</a> | </li><li><a accesskey="8" href="terms.htm" title="Terms and Conditions: access key 8">Terms and Conditions</a></li></ul></div></div></div><div id="pX"><p><a href="PHP0-publication-information.htm" rel="copyright">Copyright © BMJ Group and Pharmaceutical Press 2012. All rights reserved. </a></p></div></div><script type="text/javascript">$(document).ready(function(){$.ga('UA-9959526-1');});</script></body></html>